Comparison of the diagnostic accuracy of HE4 with CA125 and validation of the ROMA index in differentiating malignant and benign epithelial ovarian tumours among patients in Lagos, Nigeria
Open Access
- 5 July 2023
- journal article
- research article
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 17, 1568
Abstract
Comparison of the diagnostic accuracy of HE4 with CA125 and validation of the ROMA index in differentiating malignant and benign epithelial ovarian tumours amKeywords
This publication has 23 references indexed in Scilit:
- Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian massesBMC Cancer, 2013
- The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancerJournal of Ovarian Research, 2013
- Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment responseDiagnostic Pathology, 2013
- Human Epididymis Protein 4 (HE4) as a Serum Tumor Biomarker in Patients With Ovarian CarcinomaInternational Journal of Gynecological Cancer, 2011
- HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy AlgorithmBritish Journal of Cancer, 2011
- Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian massJournal of Gynecologic Oncology, 2011
- Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal massGynecologic Oncology, 2010
- A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic massGynecologic Oncology, 2009
- New tumor markers: CA125 and beyondInternational Journal of Gynecological Cancer, 2005
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983